Europe Cannabidiol Market is estimated to reach US$ 2974.87 million by 2030

Report Overview 

The Europe cannabidiol market size was valued at US$ 782.35 million in 2022 and is estimated to reach US$ 2974.87 million by 2030, exhibiting a CAGR of 18.8% during the forecast period (2023-2030).  Cannabis plants contain a component called cannabinoids, of which there are two types: cannabidiol (CBD) and tetrahydrocannabinol (THC). 

Cannabidiol (CBD) is the primary chemical compound found in cannabis plants, including both hemp and marijuana. CBD is predominantly utilized for its various health benefits, particularly in the realm of medical applications. It is employed to address a range of disorders and health conditions, including epilepsy, anxiety disorders, depression, insomnia, chronic pain, cancer-related pain, Parkinson's disease, Crohn's disease, schizophrenia, and various other ailments.  

Beyond its medical applications, CBD also finds use in the food industry, wellness and personal care products, cosmetics, and beauty products, among others. CBD is available in various forms, such as gels, gummies, oils, supplements, extracts, and more, catering to a diverse array of consumer preferences and needs. 

For More Insights Request Free Sample: https://www.datamintelligence.com/download-sample/europe-cannabidiol-market 

Market Dynamics 

The growth of the cannabidiol (CBD) market in Europe is being propelled by several key factors. These include the increasing demand for CBD products, a growing incidence of neurological disorders, psychological disorders, and chronic diseases, as well as the expanding trend of legalizations and approvals of CBD products in various European countries. Furthermore, the rising popularity of CBD-infused edible products is anticipated to further stimulate market expansion in the foreseeable future. 

The ongoing legalization and approval of CBD products play a pivotal role in driving the growth of the European CBD market. CBD products are currently in high demand due to their recognized medicinal properties. Numerous companies are actively engaged in the legalization of cannabis and its derivatives to introduce new products and address the surging demand for CBD products.  

For example, in April 2021, GW Pharmaceuticals Plc, a global company specializing in the research, development, and distribution of regulatory-approved cannabis-based medicines, announced that the European Commission (EC) had granted approval for the Type II variation application for EPIDYOLEX (cannabidiol).  

This approval pertains to its use as an adjunctive treatment for seizures associated with Tuberous sclerosis complex (TSC) in patients aged two years and older. This milestone, marking the third approved indication for GW's cannabidiol in Europe, opens up the possibility for wider accessibility of the medication throughout the continent. 

Request For Customize Report: https://www.datamintelligence.com/customize/europe-cannabidiol-market 

Market Segmentation 

By Type 

• Isolate 
• Full Spectrum 
• Broad spectrum  
• Others   

By Source  

• Marijuana 
• Hemp 

By Grade 

• Therapeutic Grade 
• Clinical Grade 
• Food Grade 

By Application 

• Pharmaceutical 
• Food & Beverages 
• Personal Care & Cosmetics 
• Others 

By Distribution Channel 

• Retail Pharmacies 
• Hospital Pharmacies 
• Online Stores 
• Others 

Market Key Players 

Major players are Akanda Corporation, Aurora Cannabis Inc., Aphria Inc., Brains Bioceutical Corporation, ENDOCA, Elixinol, NuLeaf Naturals LLC, Cannoid LLC, Isodiol International Inc., and Medical Marijuana Inc. 

Trending Reports 

Cannabidiol (CBD) Market 

Niemann-Pick Disease Type C (NPC) Market 

Phenylephrine Hydrochloride Market 

C3 Glomerulopathy Treatment Market